Therapeuticsmd Inc (TXMD) Stock Price, Quote & News

Company Profile

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is h...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 561 961 1900

Website: www.therapeuticsmd.com

Address:

951 Yamato Road, Suite 220, Boca Raton, United States

brenbto May. 12 at 11:42 PM

$TXMD The Company continues to evaluate a variety of strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not established a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary.

0 · Reply

focafoca99 May. 12 at 8:38 PM

$TXMD released its March‑quarter 2026 financial results via a press release attached to its 8‑K. https://www.rapidticker.com/news/txmd-sec-filing-2fcffd

0 · Reply

hiTHit May. 11 at 5:18 PM

$TXMD Please don’t worry, because other investors with the same IQ level are losing more than we are. We’ve performed much better than expected.🤓

2 · Reply

Bio_Invest101 May. 8 at 10:19 PM

$TXMD Vanguard Capital Management Llc ownership in TXMD / TherapeuticsMD, Inc. On May 8, 2026 - Vanguard Capital Management Llc filed a 13F-HR form disclosing ownership of 353,697 shares of TherapeuticsMD, Inc. (US:TXMD) valued at $714,468 USD as of March 31, 2026. Vanguard Fiduciary Trust Co filed a 13F-HR form disclosing ownership of 63,831 shares of TherapeuticsMD, Inc. (US:TXMD) valued at $128,939 USD as of March 31, 2026 On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 10,706 shares of TherapeuticsMD, Inc. (US:TXMD) valued at $21,626 USD as of March 31, 2026. The entity filed a previous 13F-HR on August 9, 2024 disclosing 0 shares of TherapeuticsMD, Inc.. The current value of the position is $21,519 USD.

0 · Reply

Kobe2324 May. 5 at 5:06 PM

$TXMD starting to annoy me.

0 · Reply

hiTHit May. 4 at 5:05 PM

$TXMD According to Charlie Munger, those who want to become rich should never ask this question: “What should I do to become rich?” In his view, to become rich, you should ask this question: “What should I do to become poor?”

2 · Reply

hiTHit Apr. 30 at 6:47 PM

$TXMD I want to ask this company the following: If I buy shares and the price doesn’t go up—in other words, if I don’t get rich—will you refund the money I gave you?🤓

1 · Reply

Jwilks29 Apr. 30 at 2:15 PM

$TXMD If you’re in Heron Therapuetics like many of us are, they report earnings on 5/11. There’s been a lot of speculation they’re a top candidate for a merger. Rubric also owns ~25% of their company and institutions have increased their stake this past week. They now have nearly 80% institutional ownership. Many things are lining up. Stay tuned

1 · Reply

vijalp9 Apr. 29 at 1:47 PM

$TXMD From Mayne’s Q3 report — not bad, not great. Hard to see an immediate path to clear the lowest $80M sales hurdle for the milestone payment.

1 · Reply

YPOJOB Apr. 22 at 8:25 PM

$TXMD If I can get more under 2. Just might do it. Been here this long. Why not

1 · Reply

TherapeuticsMD reports Q1 EPS 1c vs. (6c) last year

May 12, 2026, 4:05 PM EDT - 2 days ago

TherapeuticsMD Announces First Quarter 2026 Financial Results

2026-03-30T20:23:59.000Z - 6 weeks ago

TherapeuticsMD reports FY25 EPS (6c) vs. (20c) last year

Mar 30, 2026, 4:05 PM EDT - 6 weeks ago

TherapeuticsMD Announces Full Year 2025 Financial Results

2025-11-12T21:15:33.000Z - 6 months ago

TherapeuticsMD reports Q3 EPS 0c vs. (5c) last year

Nov 12, 2025, 4:05 PM EST - 6 months ago

TherapeuticsMD Announces Third Quarter 2025 Financial Results

2025-08-12T20:40:35.000Z - 9 months ago

TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year

Aug 12, 2025, 4:05 PM EDT - 9 months ago

TherapeuticsMD Announces Second Quarter 2025 Financial Results

2025-05-13T20:15:52.000Z - 1 year ago

TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year

May 13, 2025, 4:05 PM EDT - 1 year ago

TherapeuticsMD Announces First Quarter 2025 Financial Results

Mar 27, 2025, 4:05 PM EDT - 1 year ago

TherapeuticsMD Announces Full Year 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

TherapeuticsMD Announces Third Quarter 2024 Financial Results

Aug 12, 2024, 4:05 PM EDT - 1 year ago

TherapeuticsMD Announces Second Quarter 2024 Financial Results

2024-05-10T20:06:17.000Z - 2 years ago

TherapeuticsMD reports Q1 EPS (7c) vs (24c) last year

May 10, 2024, 4:05 PM EDT - 2 years ago

TherapeuticsMD Announces First Quarter 2024 Financial Results

Mar 29, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Announces Full Year 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 2 years ago

TherapeuticsMD Announces Third Quarter 2023 Financial Results

2023-08-14T10:51:58.000Z - 2 years ago

TherapeuticsMD reports Q2 EPS (24c) vs. ($1.70) last year

Aug 14, 2023, 6:50 AM EDT - 2 years ago

TherapeuticsMD Announces Second Quarter 2023 Financial Results

May 15, 2023, 4:05 PM EDT - 3 years ago

TherapeuticsMD Announces First Quarter 2023 Financial Results

Apr 7, 2023, 4:01 PM EDT - 3 years ago

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

2023-01-11T12:20:19.000Z - 3 years ago

TherapeuticsMD reinstated with a Neutral at Cantor Fitzgerald

Jan 3, 2023, 6:50 AM EST - 3 years ago

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

2022-12-05T07:39:07.000Z - 3 years ago

TherapeuticsMD Inks Licensing Deal with Mayne Pharma

2022-12-04T23:04:12.000Z - 3 years ago

TherapeuticsMD enters agreements to license products to Mayne Pharma

Dec 4, 2022, 6:00 PM EST - 3 years ago

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

2022-11-14T21:10:01.000Z - 3 years ago

TherapeuticsMD reports Q3 EPS ($3.13) vs. ($5.62) a year ago

Nov 14, 2022, 4:05 PM EST - 3 years ago

TherapeuticsMD Announces Third Quarter 2022 Financial Results

Oct 31, 2022, 6:50 AM EDT - 3 years ago

TherapeuticsMD Announces Additional $7 Million Private Placement

Oct 3, 2022, 6:50 AM EDT - 3 years ago

TherapeuticsMD Announces $7 Million Private Placement

Sep 12, 2022, 6:50 AM EDT - 3 years ago

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

Aug 15, 2022, 7:15 AM EDT - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q2 2022

Aug 15, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Announces Second Quarter 2022 Financial Results

Aug 8, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

2022-08-02T14:56:40.000Z - 4 years ago

Leading Insider Makes Private Investment in TherapeuticsMD Worth $15M

Aug 1, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

Jul 13, 2022, 8:25 AM EDT - 4 years ago

TherapeuticsMD's stock falls 41% after tender offer expires

Jul 13, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Announces Expiration of Tender Offer

Jul 6, 2022, 6:09 AM EDT - 4 years ago

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

Jun 6, 2022, 4:05 PM EDT - 4 years ago

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD

May 31, 2022, 7:34 PM EDT - 4 years ago

THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD

May 31, 2022, 1:57 PM EDT - 4 years ago

Here is why TherapeuticsMD jumped 300%

2022-05-31T13:53:53.000Z - 4 years ago

EW Healthcare Partners Acquires TherapeuticsMD; TXMD Shares Surge 350%

May 31, 2022, 6:00 AM EDT - 4 years ago

TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD

May 20, 2022, 9:43 AM EDT - 4 years ago

TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

May 16, 2022, 4:05 PM EDT - 4 years ago

TherapeuticsMD Announces First Quarter 2022 Financial Results

May 16, 2022, 9:13 AM EDT - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q1 2022

May 10, 2022, 4:05 PM EDT - 4 years ago

TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

Apr 14, 2022, 4:15 PM EDT - 4 years ago

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

GDRX

Mar 10, 2022, 8:30 AM EST - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q4 2021

Mar 10, 2022, 6:50 AM EST - 4 years ago

TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

Mar 7, 2022, 7:40 AM EST - 4 years ago

TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

GDRX

Mar 1, 2022, 4:30 PM EST - 4 years ago

TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022

Dec 10, 2021, 4:30 PM EST - 4 years ago

U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®

Dec 8, 2021, 6:50 AM EST - 4 years ago

TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date

Nov 11, 2021, 8:30 AM EST - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q3 2021

Nov 11, 2021, 6:50 AM EST - 4 years ago

TherapeuticsMD Announces Third Quarter 2021 Financial Results

Nov 11, 2021, 6:45 AM EST - 4 years ago

TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

Oct 27, 2021, 5:00 PM EDT - 4 years ago

TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021

Oct 15, 2021, 5:33 PM EDT - 4 years ago

TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer

Sep 21, 2021, 7:45 AM EDT - 5 years ago

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*

Sep 2, 2021, 6:50 AM EDT - 5 years ago

Therapeutics MD Is Urging Women to ‘Take Pause' During Menopause Awareness Month

Aug 23, 2021, 6:50 AM EDT - 5 years ago

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

brenbto May. 12 at 11:42 PM

0 · Reply

focafoca99 May. 12 at 8:38 PM

$TXMD released its March‑quarter 2026 financial results via a press release attached to its 8‑K. https://www.rapidticker.com/news/txmd-sec-filing-2fcffd

0 · Reply

hiTHit May. 11 at 5:18 PM

$TXMD Please don’t worry, because other investors with the same IQ level are losing more than we are. We’ve performed much better than expected.🤓

2 · Reply

Bio_Invest101 May. 8 at 10:19 PM

0 · Reply

Kobe2324 May. 5 at 5:06 PM

$TXMD starting to annoy me.

0 · Reply

hiTHit May. 4 at 5:05 PM

2 · Reply

hiTHit Apr. 30 at 6:47 PM

$TXMD I want to ask this company the following: If I buy shares and the price doesn’t go up—in other words, if I don’t get rich—will you refund the money I gave you?🤓

1 · Reply

Jwilks29 Apr. 30 at 2:15 PM

1 · Reply

vijalp9 Apr. 29 at 1:47 PM

$TXMD From Mayne’s Q3 report — not bad, not great. Hard to see an immediate path to clear the lowest $80M sales hurdle for the milestone payment.

1 · Reply

YPOJOB Apr. 22 at 8:25 PM

$TXMD If I can get more under 2. Just might do it. Been here this long. Why not

1 · Reply

JJYLT Apr. 21 at 5:18 PM

$TXMD mmm

0 · Reply

NYCAristocrat Apr. 20 at 9:23 PM

$TXMD Give me 5-6 and bury this POS so i don't have to look at it anymore.

1 · Reply

hiTHit Apr. 20 at 5:00 PM

$TXMD An example of a blood-borne disease? Stupidity. (No one even remembers 1/50 RS anymore)

0 · Reply

jfer333 Apr. 15 at 10:31 PM

$TXMD Case Reassigned to Judge Colm F. Connolly.

2 · Reply

JJYLT Apr. 10 at 6:22 PM

$TXMD

1 · Reply

BaneMan666 Apr. 10 at 6:09 PM

$TXMD Any update on potential deal in the works?

0 · Reply

OfficialStocktwitsUser Apr. 9 at 11:50 PM

$TXMD RSI: 39.53, MACD: -0.0550 Vol: 0.11, MA20: 2.15, MA50: 2.23 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

YPOJOB Apr. 9 at 11:14 PM

$TXMD Stop toying with me TXMD just get something done. Once again I hate the courts. Just get whatever it is done now! I know patience.

0 · Reply

jfer333 Apr. 7 at 1:10 AM

$TXMD I think the market is missing a key dynamic here ..:. If Mayne is actually trying to divest U.S. assets, this situation is far from clean. There’s an active ~$15–20M legal dispute, a forced BDO process, and ongoing litigation — plus these assets are tied up in licensing, manufacturing, and IP connected back to TXMD. In reality, Mayne likely can’t just sell this to a third party cleanly, especially without TXMD’s involvement or consent. Any buyer would be stepping into uncertainty + disputed economics. That’s what makes this interesting… TXMD may not just be a buyer — they may be a necessary party to any exit. And if that leads to a buyback/unwind at a discount (say ~$30M less than the original deal), you’re talking about a completely different company overnight. TXMD goes from a ~$30M royalty shell to owning operating assets again — that’s where a real re-rating into the $5–$10+ range starts to make sense depending on structure. That’s the kind of pay day Rubric goes after …

2 · Reply

jfer333 Apr. 7 at 1:01 AM

$TXMD— big legal update (last 2 filings): 1. Court ruled: 👉 Dispute goes to BDO (expert accounting review) 👉 Case is stayed (paused) 2. TXMD just responded: 👉 Filed formal objection 👉 Arguing BDO is optional, not mandatory 👉 Wants to stay in court (to get discovery) ⸻ What this means: • TXMD is basically saying: 👉 “We can’t win this as just a math problem” •They want: 👉 Access to Mayne’s internal data (sales, returns, etc.) ⸻ Current situation: • BDO = fast, limited, numbers only • Court = slower, but full investigation 👉 TXMD trying to shift from accounting fight → behavior/fraud case ⸻ My read: • Odds still favor BDO moving forward • BUT this adds pressure + complexity 👉 More uncertainty = more incentive to settle ⸻ Translation: This just became less “who wins the math” and more “how do both sides resolve this” 👀

0 · Reply

Kobe2324 Mar. 31 at 7:32 PM

$TXMD how many years have we been looking for strategic alternatives. Come on alreadyyyyyyyyy

0 · Reply

vijalp9 Mar. 30 at 11:19 PM

$TXMD FY2025 Earnings are out. At a quick glance, TXMD top line revenue is essentially Mayne’s annual minimum payment as per their product licensing agreement.

0 · Reply

Market Cap	23.38M
Revenue (ttm)	3.02M
Net Income (ttm)	-570,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.87%
Debt to Equity Ratio	0.00

Volume	8,900
Avg Vol	22,304
Day's Range	N/A - N/A
Shares Out	11.57M
Stochastic %K	39%
Beta	0.58
Analysts	Strong Buy
Price Target	$5.00